FDA says it will take 'weeks' to deliver more baby formula to store shelves




  • In Politics
  • 2022-05-17 17:14:46Z
  • By NBC News

The U.S. Food and Drug Administration has announced new measures to boost baby formula supplies amid a severe shortage that has sent American parents scrambling.

The FDA said Monday it was streamlining the ability of infant formula makers globally to sell their products in the U.S., waiving certain trade barriers to allow formula intended for foreign markets to be sold here. It also said it was encouraging domestic distribution of U.S.-manufactured products intended for export to foreign countries.

Still, even with those waivers, the FDA acknowledged it could take "weeks" for new product to hit U.S. store shelves.

"Today's action paves the way for companies who don't normally distribute their infant formula products in the U.S. to do so efficiently and safely," FDA Commissioner Robert M. Califf said in a statement. "We are hopeful this call to the global market will be answered and that international businesses will rise to the occasion to assist in bolstering the supply of products that serve as the sole source of nutrition for many infants."

Last week, the Biden administration said it was seeking to reduce red tape on formula production and imports.

A woman shops for baby formula (Jim Watson / AFP - Getty Images)
A woman shops for baby formula (Jim Watson / AFP - Getty Images)  

At least one company, Nestle S.A. - maker of Gerber baby formula - said Tuesday it was beginning to fly in supplies of formula from its overseas facilities to the U.S.

"We moved shipments up and rushed via air to help fill immediate needs," the company said in a statement, adding that it was also reviewing the FDA's guidance and assessing where it may be able to "tap into the Nestlé global nutrition network to help."

The U.S. normally produces 98 percent of the infant formula it consumes, the FDA said. But supplies have diminished since February, when a key plant in Sturgis, Michigan, operated by Abbott Laboratories, shut down over a suspected link to the deaths of two infants from bacterial infections.

The FDA also announced this week that it had reached an agreement with Abbott to begin reopening that Michigan facility; a court must now approve the agreement before it takes effect. Abbott previously said it would take up to two weeks to restart the plant, and another six to eight weeks for product to become available in stores.

The FDA also sought to portray the formula shortage as less severe than believed Monday, citing new data from Information Resources Inc. (IRI), a market research group, that showed lower out-of-stock rates than an alternative data source.

According to IRI, approximately 20 percent of regular supplies are missing from store shelves, compared with an average of 43 percent cited by the market research group Datasembly. IRI also reported formula sales were higher in April compared to the month prior to the February recall that kicked off the shortage.

Among others, Target said in a statement Monday that it still had some online and in-store formula product limitations in place.

In a recent statement to NBC, the CEO of Perrigo, a private-label formula manufacturer, said its shortages would likely last for the balance of the year.

COMMENTS

More Related News

FDA won
FDA won't require lengthy clinical trials for COVID-19 boosters

Future COVID-19 vaccine boosters won't have to go through a traditional, lengthy clinical trial process to attain emergency use authorization in the U.S., according to a report in Reuters. An agency official, speaking to the publication today, said that the U.S. Food and Drug Administration (FDA) will instead rely on data from trials on shots developed earlier in the pandemic to combat specific virus variants as well as manufacturing data in considering whether to clear boosters for administration. Preclinical animal study and safety data might also be used, the official said.

FDA will not require clinical trial data to authorize redesigned COVID boosters -official
FDA will not require clinical trial data to authorize redesigned COVID boosters -official
  • US
  • 2022-06-30 20:49:07Z

The U.S. Food and Drug Administration will not require companies to submit clinical trial data on COVID-19 vaccines modified to protect against the BA.4 and BA.5 Omicron subvariants in order to authorize those shots, a top FDA official said on Thursday. Dr. Peter Marks, head of the agency's Center for Biologics Evaluation and Research, told Reuters the agency will rely on data from clinical trials vaccine makers have run on shots designed to combat the BA.1 Omicron variant, as well as manufacturing data, for emergency use authorization submissions before the fall. The FDA on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall...

FDA asks COVID-19 vaccine makers to update boosters to target new Omicron variants
FDA asks COVID-19 vaccine makers to update boosters to target new Omicron variants

The BA.4 and BA.5 strains now account for over half of infections in the US, according to the CDC.

FDA recommends inclusion of BA.4, BA.5 subvariants in COVID boosters
FDA recommends inclusion of BA.4, BA.5 subvariants in COVID boosters
  • US
  • 2022-06-30 14:18:56Z

The FDA said it has not advised manufacturers to change the vaccine for the primary vaccination series, saying the coming year will be "a transitional period...

Pfizer asks for formal U.S. approval of oral COVID treatment Paxlovid
Pfizer asks for formal U.S. approval of oral COVID treatment Paxlovid
  • US
  • 2022-06-30 10:48:42Z

Pfizer said it submitted a New Drug Application for Paxlovid to the Food and Drug Administration for the treatment of COVID-19 in vaccinated and unvaccinated...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Politics